Match!

Demand cancer drugs that truly help patients

Published on Apr 1, 2018in Nature43.07
· DOI :10.1038/d41586-018-04154-9
Ajay Aggarwal1
Estimated H-index: 1
Cite
Abstract
Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal. Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal.
  • References (0)
  • Citations (1)
Cite
References0
Newest
Cited By1
Newest
Published on Apr 17, 2019
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Jennifer Taher6
Estimated H-index: 6
(U of T: University of Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
Background: The term P4 medicine (predictive, preventative, personalized, participatory) was coined by Dr. Leroy Hood of the Institute for Systems Biology to demonstrate his framework to detect and prevent disease through extensive biomarker testing, close monitoring, deep statistical analysis, and patient health coaching. Methods: In 2017, this group published the results of their “100 Person Wellness Project.” They performed whole genome sequencing and 218 clinical laboratory tests, measured 6...
Published on Feb 1, 2019in Lancet Oncology35.39
Yolande Lievens29
Estimated H-index: 29
(Ghent University Hospital),
Riccardo A. Audisio3
Estimated H-index: 3
(Sahlgrenska University Hospital)
+ 5 AuthorsAjay Aggarwal7
Estimated H-index: 7
('KCL': King's College London)
Summary Surgery and radiotherapy, two locoregional cancer treatments, are essential to help improve cancer outcomes, control, and palliation. The continued evolution in treatment processes, techniques, and technologies—often at substantially increased costs—demands for direction on outcomes that are most valued by patients, and the evidence that is required before clinical adoption of these practices. Three recently introduced frameworks—the European Society for Medical Oncology Magnitude of Cli...